Findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024 – Cancer Network
Cancer Network shared a post on X:
“Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.”
Paolo Tarantino, Clinical Research Fellow at the Dana-Farber Cancer Institute, reshared the post on X, adding:
“Fun and insightful post-SABCS chat with powerhouse Matteo Lambertini.
Thanks CancerNetwork® for coordinating this podcast!”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School. He completed a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023